BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Azacitidine: trial readouts and FDA decisions
4 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Sellas Life Sciences Group, OncoVerity, Inc., AbbVie, Aptose Biosciences Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-01 est. | P2 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | NCT06858618 FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms | Safety; Antitumor Activity; PK Profile | active not recruiting | 47 |
| 2026-12-30 est. | P1/P2 | Sellas Life Sciences Group SLS | NCT04588922 Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | Hematologic Malignancies | recruiting | 160 |
| 2027-01 est. | P2 | OncoVerity, Inc. | NCT06384261 A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | Leukemia, Myeloid, Acute | active not recruiting | 140 |
| 2027-02 est. | P1/P2 | AbbVie ABBV | NCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | Acute Myeloid Leukemia | active not recruiting | 218 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P1/P2 | Aptose Biosciences Inc. | NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute | Leukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML; Myelodysplastic Syndrome With Excess B | recruiting | 240 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.